Dipharma Francis S.r.l. completes acquisition of Kalexsyn, Inc.
Milan, Italy – Dipharma Francis S.r.l., (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients, is pleased to communicate that it has completed its previously announced acquisition of Kalexsyn, Inc. (Kalexsyn), a world-class Contract Research Organization (CRO) providing chemistry services to the biotechnology and pharmaceutical industry. Pursuant to an agreement dated March 19, 2018, Dipharma has acquired all of the issued and outstanding shares of Kalexsyn through its American subsidiary Dipharma, Inc. Kalexsyn, based in Kalamazoo, Michigan (USA), was founded in 2003 and provides chemistry services that support the drug discovery and development activities of their customers.
Experienced Medicinal Chemistry
The merits of the one-stop shop is a topic of perennial debate in business management circles. On one side of the argument is the proposition that a vendor’s full menu of services or products allows customers to consolidate suppliers. The other side argues that no one supplier can deliver the same high level of quality and service for each item on the menu. Read more
Ernst &Young Entrepreneurs
Kalexsyn Inc. co-founders David Zimmermann and Robert Gadwood, Ph.D. have been named Entrepreneurs of the Year by Ernst & Young.
Zimmermann and Gadwood, who formed Kalexsyn in 2003, received the award in the technology category for the Michigan and Northwest Ohio region.